FCM
Farallon Capital Management Portfolio holdings
AUM
$21.3B
This Quarter Return
+22.23%
1 Year Return
+23.12%
3 Year Return
+87.19%
5 Year Return
+183.94%
10 Year Return
+836.54%
AUM
$12.1B
AUM Growth
+$12.1B
(+6%)
Cap. Flow
-$1.14B
Cap. Flow
% of AUM
-9.39%
Top 10 Holdings %
Top 10 Hldgs %
48.07%
Holding
116
New
19
Increased
27
Reduced
27
Closed
22
Top Buys
| 1 |
CELG
Celgene Corp
CELG
|
$795M |
| 2 |
S&P Global
SPGI
|
$192M |
| 3 |
Sherwin-Williams
SHW
|
$165M |
| 4 |
Sea Limited
SE
|
$163M |
| 5 |
WCG
Wellcare Health Plans, Inc.
WCG
|
$151M |
Top Sells
| 1 |
TFCFA
Twenty-First Century Fox, Inc. Class A
TFCFA
|
$616M |
| 2 |
TFCF
Twenty-First Century Fox, Inc. Class B
TFCF
|
$370M |
| 3 |
Equinix
EQIX
|
$315M |
| 4 |
Meta Platforms (Facebook)
META
|
$204M |
| 5 |
Alphabet (Google) Class C
GOOG
|
$202M |
Sector Composition
| 1 | Healthcare | 29.96% |
| 2 | Technology | 22.53% |
| 3 | Communication Services | 18.58% |
| 4 | Industrials | 7.24% |
| 5 | Consumer Discretionary | 6.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Cigna
CI
$80.3B
| $152M | 1.14% | 945,000 -110,000 | -10% | -$17.7M |
|
|
WCG
27
DELISTED
Wellcare Health Plans, Inc.
WCG
| $151M | 1.14% | +560,000 | New | +$151M |
|
|
GG
28
DELISTED
Goldcorp Inc
GG
| $148M | 1.12% | +12,960,000 | New | +$148M |
|
|
ARRY
29
DELISTED
Array Biopharma Inc
ARRY
| $134M | 1.01% | 5,500,000 -250,000 | -4% | -$6.1M |
|
|
ARRS
30
DELISTED
ARRIS International plc Ordinary Shares
ARRS
| $118M | 0.89% | 3,745,000 +165,000 | +5% | +$5.22M |
|
|
ZGNX
31
DELISTED
Zogenix, Inc.
ZGNX
| $113M | 0.85% | 2,050,500 | – | – |
|
|
XLRN
32
DELISTED
Acceleron Pharma Inc.
XLRN
| $111M | 0.83% | 2,375,000 +275,000 | +13% | +$12.8M |
|
33
Liberty Global Class C
LBTYK
$4.07B
| $104M | 0.78% | 4,308,106 -629,096 | -13% | -$15.2M |
|
|
MYOK
34
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $101M | 0.76% | 1,950,278 +350,000 | +22% | +$18.2M |
|
35
Fox Class B
FOX
$24.3B
| $101M | 0.76% | +2,807,431 | New | +$101M |
|
36
Liberty Global Class A
LBTYA
$4B
| $98.4M | 0.74% | 3,949,553 -2,022,884 | -34% | -$50.4M |
|
|
SAGE
37
DELISTED
Sage Therapeutics
SAGE
| $95.4M | 0.72% | 600,000 +200,000 | +50% | +$31.8M |
|
|
ONCE
38
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $93.4M | 0.7% | +820,000 | New | +$93.4M |
|
39
Enanta Pharmaceuticals
ENTA
$180M
| $89.8M | 0.68% | 940,000 +15,000 | +2% | +$1.43M |
|
|
MRTX
40
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $88M | 0.66% | 1,200,000 -100,000 | -8% | -$7.33M |
|
|
GBT
41
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $79.4M | 0.6% | 1,500,000 +50,000 | +3% | +$2.65M |
|
42
Sarepta Therapeutics
SRPT
$1.78B
| $77.5M | 0.58% | 650,000 +10,000 | +2% | +$1.19M |
|
43
Alibaba
BABA
$322B
| $75.7M | 0.57% | 415,000 -635,000 | -60% | -$116M |
|
44
Exelixis
EXEL
$10.1B
| $71.4M | 0.54% | 3,000,000 +1,000,000 | +50% | +$23.8M |
|
|
AMRN
45
Amarin Corp
AMRN
$311M
| $67.5M | 0.51% | 3,250,000 -250,000 | -7% | -$5.19M |
|
|
RETA
46
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $64.1M | 0.48% | 750,000 +50,000 | +7% | +$4.27M |
|
47
Grifois
GRFS
$6.78B
| $58.8M | 0.44% | 2,926,352 +545,233 | +23% | +$11M |
|
48
Iovance Biotherapeutics
IOVA
$807M
| $54.4M | 0.41% | 5,725,000 | – | – |
|
49
NovoCure
NVCR
$1.38B
| $50.6M | 0.38% | 1,050,000 -200,000 | -16% | -$9.63M |
|
50
FibroGen
FGEN
$47.8M
| $49.8M | 0.37% | 915,579 +165,579 | +22% | +$9M |
|